Should I buy or sell CymaBay Therapeutics stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last twelve months. There are currently 11 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CBAY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CBAY, but not buy additional shares or sell existing shares. View CBAY analyst ratings or view top-rated stocks .

What is CymaBay Therapeutics' stock price target for 2024?

12 brokerages have issued 12 month price objectives for CymaBay Therapeutics' stock. Their CBAY share price targets range from $15.00 to $32.50. On average, they predict the company's share price to reach $28.65 in the next year. This suggests that the stock has a possible downside of 11.8%. View analysts price targets for CBAY or view top-rated stocks among Wall Street analysts .

How have CBAY shares performed in 2024?

CymaBay Therapeutics' stock was trading at $23.62 at the start of the year. Since then, CBAY shares have increased by 37.5% and is now trading at $32.48. View the best growth stocks for 2024 here .

When is CymaBay Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our CBAY earnings forecast .

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) announced its earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.04. The biopharmaceutical company had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.42 million.

What ETFs hold CymaBay Therapeutics' stock?

ETFs with the largest weight of CymaBay Therapeutics (NASDAQ:CBAY) stock in their portfolio include AltShares Merger Arbitrage ETF (ARB) and AltShares Event-Driven ET (EVNT) . AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC) .

What other stocks do shareholders of CymaBay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE) , NVIDIA (NVDA) , Advanced Micro Devices (AMD) , OPKO Health (OPK) , Pfizer (PFE) , Alibaba Group (BABA) , Novavax (NVAX) , Corbus Pharmaceuticals (CRBP) , Energy Transfer (ET) and Viking Therapeutics (VKTX) .

How do I buy shares of CymaBay Therapeutics?

Shares of CBAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CBAY

CymaBay Therapeutics (CBAY) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free CBAY Stock Alerts

$32.48

0.00 (0.00%)

(As of 04/1/2024)

Compare

Today's Range: $32.48
▼
$32.48
50-Day Range: $24.96
▼
$32.48
52-Week Range: $7.26
▼
$32.50

Volume: 73 shs
Average Volume: 4.11 million shs
Market Capitalization: $3.73 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $28.65

Get CymaBay Therapeutics alerts:

CymaBay Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Hold
2.08 Rating Score
Upside/Downside: 11.8% Downside
$28.65 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: -0.88
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$627,419 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.38) to ($1.37) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.90 out of 5 stars

Medical Sector

815th out of 918 stocks

Pharmaceutical Preparations Industry

359th out of 402 stocks

2.0

Analyst's Opinion

Consensus Rating
CymaBay Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.08, and is based on 1 buy rating, 11 hold ratings, and no sell ratings.
Amount of Analyst Coverage
CymaBay Therapeutics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

N/A

Short Interest

Short Interest
There is no current short interest data available for CBAY.

0.0

Dividend Strength

Dividend Yield
CymaBay Therapeutics does not currently pay a dividend.
Dividend Growth
CymaBay Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
CymaBay Therapeutics has received a 74.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for CymaBay Therapeutics is -0.88.

0.0

News and Social Media Coverage

Search Interest
Only 1 people have searched for CBAY on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added CymaBay Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -88% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CymaBay Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $627,419.00 in company stock.
Percentage Held by Insiders
Only 7.00% of the stock of CymaBay Therapeutics is held by insiders.
Percentage Held by Institutions
95.03% of the stock of CymaBay Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for CymaBay Therapeutics are expected to grow in the coming year, from ($1.38) to ($1.37) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of CymaBay Therapeutics is -33.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of CymaBay Therapeutics is -33.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
CymaBay Therapeutics has a P/B Ratio of 12.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About CymaBay Therapeutics Stock (NASDAQ:CBAY)

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.

CBAY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CBAY Stock News Headlines

April 11, 2024 | americanbankingnews.com

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Given Average Recommendation of "Hold" by Brokerages

April 11, 2024 | americanbankingnews.com

CymaBay Therapeutics (NASDAQ:CBAY) Coverage Initiated by Analysts at StockNews.com

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 22, 2024 | za.investing.com

Gilead reduces 2024 earnings guidance after completing CymaBay takeover

March 22, 2024 | markets.businessinsider.com

Gilead Sciences Completes Acquisition Of CymaBay Therapeutics

March 22, 2024 | businesswire.com

Gilead Sciences Announces Completion of Acquisition of CymaBay

March 16, 2024 | finance.yahoo.com

CBAY Jul 2024 34.000 call

March 16, 2024 | finance.yahoo.com

CBAY Apr 2024 31.000 put

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 16, 2024 | finance.yahoo.com

CBAY Oct 2024 33.000 call

March 16, 2024 | finance.yahoo.com

CBAY Oct 2024 29.000 put

March 11, 2024 | finance.yahoo.com

Investing in CymaBay Therapeutics (NASDAQ:CBAY) three years ago would have delivered you a 540% gain

March 4, 2024 | globenewswire.com

CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis

February 29, 2024 | markets.businessinsider.com

Maintaining Hold on CymaBay Amid Gilead Acquisition Deal Closure

February 29, 2024 | markets.businessinsider.com

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of CymaBay Therapeutics, Inc. (CBAY)

February 28, 2024 | marketwatch.com

CymaBay Therapeutics 4Q Loss/Shr 35c >CBAY

February 28, 2024 | globenewswire.com

CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update

February 24, 2024 | msn.com

CymaBay Therapeutics (CBAY) Price Target Increased by 12.84% to 31.37

February 21, 2024 | finance.yahoo.com

The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis

February 21, 2024 | prnewswire.com

The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis

February 20, 2024 | msn.com

Leerink Partners Downgrades CymaBay Therapeutics (CBAY)

February 20, 2024 | globenewswire.com

CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 16, 2024 | businesswire.com

CYMABAY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CymaBay Therapeutics, Inc. - CBAY

February 15, 2024 | finance.yahoo.com

CBAY Jan 2026 37.000 call

February 14, 2024 | finance.yahoo.com

CBAY Feb 2024 33.000 call

February 14, 2024 | finance.yahoo.com

CBAY Jan 2025 8.000 put

February 13, 2024 | seekingalpha.com

CymaBay's Seladelpar Is A Solid, But Pricey, Addition To Gilead's Liver Franchise

See More Headlines

Receive CBAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CBAY
CUSIP: N/A
CIK: 1042074
Web: www.cymabay.com
Phone: (510) 293-8800
Fax: 510-293-9090
Employees: 101
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $28.65
High Stock Price Target: $32.50
Low Stock Price Target: $15.00
Potential Upside/Downside: -11.8%
Consensus Rating: Hold
Rating Score (0-4): 2.08
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.97)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-105,370,000.00
Net Margins: N/A
Pretax Margin: -339.11%
Return on Equity: -50.72%
Return on Assets: -31.04%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.96
Quick Ratio: 10.96

Sales & Book Value

Annual Sales: $31.07 million
Price / Sales: 119.92
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.58 per share
Price / Book: 12.59

Miscellaneous

Outstanding Shares: 114,724,000
Free Float: 106,693,000
Market Cap: $3.73 billion
Optionable: Optionable
Beta: 0.32

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Sujal A. Shah (Age 51)
President, CEO & Director
Comp: $1.04M
Dr. Charles A. McWherter Ph.D. (Age 69)
President of Research & Development and Chief Scientific Officer
Comp: $700.65k
Mr. Paul T. Quinlan (Age 61)
General Counsel, Chief Compliance Officer & Corporate Secretary
Comp: $629.72k
Mr. Harish Shantharam C.F.A. (Age 42)
CFO, Principal Accounting & Financial Officer
Mr. Ken Boehm
Senior Vice President of Human Resources
Mr. Patrick J. O'Mara (Age 63)
Senior Vice President of Business Development
Dr. Robert L. Martin (Age 62)
Senior Vice President of Manufacturing & Nonclinical Development
Ms. Klara A. Dickinson-Eason (Age 56)
Chief Regulatory & Quality Assurance Officer
Comp: $441.84k
Ms. Becki Filice (Age 63)
Senior Vice President of Portfolio & Product Leadership
Mr. Ben Kozub
Head of Commercial

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CBAY Stock Analysis - Frequently Asked Questions

Should I buy or sell CymaBay Therapeutics stock right now?: 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last twelve months. There are currently 11 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CBAY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CBAY, but not buy additional shares or sell existing shares.
View CBAY analyst ratings or view top-rated stocks.
What is CymaBay Therapeutics' stock price target for 2024?: 12 brokerages have issued 12 month price objectives for CymaBay Therapeutics' stock. Their CBAY share price targets range from $15.00 to $32.50. On average, they predict the company's share price to reach $28.65 in the next year. This suggests that the stock has a possible downside of 11.8%.
View analysts price targets for CBAY or view top-rated stocks among Wall Street analysts.
How have CBAY shares performed in 2024?: CymaBay Therapeutics' stock was trading at $23.62 at the start of the year. Since then, CBAY shares have increased by 37.5% and is now trading at $32.48.
View the best growth stocks for 2024 here.
When is CymaBay Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our CBAY earnings forecast.

How were CymaBay Therapeutics' earnings last quarter?: CymaBay Therapeutics, Inc. (NASDAQ:CBAY) announced its earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.04. The biopharmaceutical company had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.42 million.
What ETFs hold CymaBay Therapeutics' stock?: ETFs with the largest weight of CymaBay Therapeutics (NASDAQ:CBAY) stock in their portfolio include AltShares Merger Arbitrage ETF (ARB) and AltShares Event-Driven ET (EVNT).AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC).
What other stocks do shareholders of CymaBay Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET) and Viking Therapeutics (VKTX).
How do I buy shares of CymaBay Therapeutics?: Shares of CBAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CBAY) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

CymaBay Therapeutics (CBAY) Stock Price, News & Analysis

CymaBay Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About CymaBay Therapeutics Stock (NASDAQ:CBAY)

CBAY Stock Price History

CBAY Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

CBAY Stock Analysis - Frequently Asked Questions

Overall MarketRank^™